

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Benzodiazepine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Orphan Drug Designation to MicuRx's MRX-5 for NTM Infections
Details : MRX-5, a novel oral oxaborole prodrug, which is being evaluated in the early-stage clinical trial studies for the treatment of non-tuberculous mycobacterial infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 01, 2025
Lead Product(s) : Benzodiazepine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Benzodiazepine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia
Details : MRX-5, a novel oral oxaborole prodrug, which is being evaluated in the early-stage clinical trial studies for the treatment of non-tuberculous mycobacterial infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 25, 2024
Lead Product(s) : Benzodiazepine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Benzodiazepine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MicuRx Pharmaceuticals Announces Results from MRX-5 Study For Mycobacterium Infections
Details : MRX-5, a novel oral oxaborole prodrug, which is being evaluated in the early-stage clinical trial studies for the treatment of non-tuberculous mycobacteria infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 07, 2024
Lead Product(s) : Benzodiazepine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Benzodiazepine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First Subject Enrolled in Phase 1 Study of MRX-5
Details : MRX-5 is a new type of benzodiazepine antibiotic used to treat infections caused by NTMs, non-tuberculosis mycobacteria refers to a large class of bacteria, excluding Mycobacteria tuberculosis, which causes chronic lung infections and results in lung dam...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 20, 2023
Lead Product(s) : Benzodiazepine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Benzodiazepine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Hamilton Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free)
Details : Benzodiazepine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Emergence Delirium.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 15, 2017
Lead Product(s) : Benzodiazepine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Hamilton Health Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
